- Home
- FINW vs CRVS Comparison
FINW vs CRVS Comparison
Compare FINW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CRVS
- Stock Information
- Founded
- FINW 1999
- CRVS 2014
- Country
- FINW United States
- CRVS United States
- Employees
- FINW N/A
- CRVS N/A
- Industry
- FINW Commercial Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- CRVS Health Care
- Exchange
- FINW Nasdaq
- CRVS Nasdaq
- Market Cap
- FINW 261.6M
- CRVS 459.0M
- IPO Year
- FINW 2021
- CRVS 2016
- Fundamental
- Price
- FINW $19.82
- CRVS $5.79
- Analyst Decision
- FINW Buy
- CRVS Strong Buy
- Analyst Count
- FINW 4
- CRVS 4
- Target Price
- FINW $20.75
- CRVS $15.00
- AVG Volume (30 Days)
- FINW 11.1K
- CRVS 547.2K
- Earning Date
- FINW 10-23-2025
- CRVS 11-11-2025
- Dividend Yield
- FINW N/A
- CRVS N/A
- EPS Growth
- FINW N/A
- CRVS N/A
- EPS
- FINW 0.96
- CRVS N/A
- Revenue
- FINW $74,999,000.00
- CRVS N/A
- Revenue This Year
- FINW $52.89
- CRVS N/A
- Revenue Next Year
- FINW $20.66
- CRVS N/A
- P/E Ratio
- FINW $20.45
- CRVS N/A
- Revenue Growth
- FINW 10.21
- CRVS N/A
- 52 Week Low
- FINW $13.49
- CRVS $2.54
- 52 Week High
- FINW $20.94
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FINW 62.07
- CRVS 56.88
- Support Level
- FINW $19.15
- CRVS $5.64
- Resistance Level
- FINW $19.79
- CRVS $6.09
- Average True Range (ATR)
- FINW 0.59
- CRVS 0.34
- MACD
- FINW -0.05
- CRVS -0.05
- Stochastic Oscillator
- FINW 72.85
- CRVS 50.00
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).